|
|
|
| Urban-rural difference in adverse outcomes of pulmonary tuberculosis in patients with pulmonary tuberculosis-diabetes mellitus comorbidity |
| FANG Zijian, LI Qingchun, XIE Li, SONG Xu, DAI Ruoqi, WU Yifei, JIA Qingjun, CHENG Qinglin
|
| Hangzhou Center for Disease Control and Prevention (Hangzhou Health Supervision Institute),Hangzhou, Zhejiang 310021, China |
|
|
|
|
Abstract Objective To investigate the urban and rural differences in adverse outcomes of pulmonary tuberculosis (PTB) in patients with pulmonary tuberculosis-diabetes mellitus comorbidity (PTB-DM), so as to provide insights into improving the prevention and treatment measures for PTB-DM. Methods Patients with PTB-DM who were admitted and discharged from 14 designated tuberculosis hospitals in Hangzhou City from 2018 to 2022 were selected. Basic information, and history of diagnosis and treatment were collected through hospital information systems. The adverse outcomes of PTB were defined as endpoints, and the proportions of adverse outcomes of PTB in urban and rural patients with PTB-DM were analyzed. Factors affecting the adverse outcomes of PTB were identified using a multivariable Cox proportional hazards regression model. Results A total of 823 patients with PTB-DM were enrolled, including 354 (43.01%) urban and 469 (56.99%) rural patients. There were 112 (13.61%) patients with adverse outcomes of PTB. The proportions of adverse outcomes of PTB in urban and rural patients were 14.41% and 13.01%, respectively, with no statistically significant difference (P>0.05). Multivariable Cox proportional hazards regression analysis identified first diagnosed in county-level hospitals or above (HR=2.107, 95%CI: 1.181-3.758) and drug resistance (HR=3.303, 95%CI: 1.653-6.600) as the risk factors for adverse outcomes of PTB in urban patients with PTB-DM, while the treatment/observed management throughout the process (HR=0.470, 95%CI: 0.274-0.803) and fixed-dose combinations throughout the process (HR=0.331, 95%CI: 0.151-0.729) as the protective factors for adverse outcomes in rural patients with PTB-DM. Conclusions There are differences in influencing factors for adverse outcomes of PTB in urban and rural patients with PTB-DM. The adverse outcomes of PTB are associated with first diagnosed hospitals and drug resistance in urban patients, and are associated with the treatment/observed management and fixed-dose combinations throughout the process in rural patients.
|
|
Received: 06 August 2024
Revised: 05 December 2024
Published: 14 January 2025
|
|
|
|
|
|
[1] International Diabetes Federation.IDF diabetes atlas[EB/OL].[2024-12-05].https://diabetesatlas.org/atlas/tenth-edition.
[2] AI-RIFAI R H,PEARSON F,CRITCHLEY J A,et al.Association between diabetes mellitus and active tuberculosis:a systematic review and meta-analysis[J/OL]. PLoS One,2017,12(11)[2024-12-05].https://doi.org/10.1371/journal.pone.0187967.
[3] GEZAHEGN H,IBRAHIM M,MULAT E.Diabetes mellitus and tuberculosis comorbidity and associated factors among Bale Zone health institutions,Southeast Ethiopia[J].Diabetes Metab Syndr Obes,2020,13:3879-3886.
[4] ZHANG S J,TONG X,WANG L,et al.Clinical characteristics and prognostic analysis of patients with pulmonary tuberculosis and type 2 diabetes comorbidity in China:a retrospective analysis[J/OL].Front Public Health,2021,9[2024-12-05].https://doi.org/10.3389/fpubh.2021.710981.
[5] 中华人民共和国国家卫生和计划生育委员会.肺结核诊断标准:WS 288—2017[S].北京:中国标准出版社,2017.
National Health and Family Planning Commission of the People's Republic of China.Diagnostic criteria for tuberculosis:WS 288—2017[S].Beijing:Standards Press of China,2017.(in Chinese)
[6] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.
Chinese Diabetes Society.Guidelines for the prevention and control of type 2 diabetes in China (2020 edition)[J].Chin J Diabetes Mellitus,2021,13(4):315-409.(in Chinese)
[7] 中华人民共和国国家卫生健康委员会.中国结核病预防控制工作技术规范(2020版)[S].北京:人民卫生出版社,2020.
National Health Commission of the People's Republic of China.Technical specifications for TB prevention and control in China (2020 edition)[S].Beijing:People's Medical Publishing House,2020.(in Chinese)
[8] CHENG Q L,XIE L,WU Y,et al.Impact of different tuberculosis history at the onset of future multidrug-resistant tuberculosis:a large,retrospective,population-based cohort study[J].J Glob Antimicrob Resist,2021,24:158-168.
[9] 国家统计局.统计上划分城乡的规定[EB/OL].[2024-12-05].https://www.stats.gov.cn/sj/tjbz/gjtjbz/202302/t20230213_1902742.html.
[10] 杨蕊,李玲,陈金瓯,等.2017—2021年云南省肺结核与糖尿病共病患者抗结核治疗效果及影响因素分析[J]. 中国防痨杂志,2024,46(5):519-524.
YANG R,LI L,CHEN J O,et al.Analysis of influencing factors of anti-tuberculosis treatment effect for pulmonary tuberculosis patients complicated with diabetes in Yunnan Province from 2017 to 2021[J].Chin J Antituberc,2024,46(5):519-524.(in Chinese)
[11] 王铂,马玉宝,郭强,等.2018—2021年甘肃省肺结核合并糖尿病患者特征及治疗转归影响因素分析[J].疾病监测,2024,39(6):771-775.
WANG B,MA Y B,GUO Q,et al.Characteristics of pulmonary tuberculosis patients complicated with diabetes and factors influencing treatment outcome in Gansu,2018-2021[J].Dis Surveill,2024,39(6):771-775.(in Chinese)
[12] JIANG W X,TRIMAWARTINAH,RAHMAN F M,et al.The co-management of tuberculosis-diabetes co-morbidities in Indonesia under the national tuberculosis control program:results from a cross-sectional study from2017 to 2019[J/OL].BMC Public Health,2022,22(1)[2024-12-05].https://doi.org/10.1186/s12889-022-13017-y.
[13] WILLIAMS V,VOS A,OTWOMBE K,et al.Epidemiology and control of diabetes - tuberculosis comorbidity in Eswatini:protocol for the prospective study of tuberculosis patients on predictive factors,treatment outcomes and patient management practices[J/OL].BMJ Open,2022,12(6)[2024-12-05].https://doi.org/10.1136/bmjopen-2021-059254.
[14] 刘宇丹,张彩云,郭明媚,等.慢性病共病患者服药依从性影响因素的Meta分析[J].预防医学,2024,36(9):790-800.
LIU Y D,ZHANG C Y, GUO M M,et al.Influencing factors for medication compliance in patients with comorbidities of chronic diseases:a meta-analysis[J].China Prev Med J,2024,36(9):790-800.(in Chinese)
[15] PENG X,MENG L,QI J,et al.Trends of drug-resistant tuberculosis in an urban and a rural area in China: a 10-year population-based molecular epidemiological study[J].Infect Drug Resist,2024,17:919-926.
[16] 吴倩,张钰,刘魁,等.2016—2020年浙江省肺结核流行特征分析[J].预防医学,2022,34(5):487-491.
WU Q,ZHANG Y,LIU K,et al.Epidemiological characteristics of pulmonary tuberculosis in Zhejiang Province from 2016 to 2020[J].China Prev Med J,2022,34(5):487-491.(in Chinese)
[17] 张婷,刘珊珊,汪清雅,等.重庆市疾控机构耐药肺结核治疗管理评价指标体系构建[J].预防医学,2021,33(6):592-598.
ZHANG T,LIU S S,WANG Q Y,et al.Construction of the evaluation system for treatment and management of drug-resistant tuberculosis in Centers of Disease Control and Prevention in Chongqing[J].China Prev Med J,2021,33(6):592-598.(in Chinese)
[18] 王倪,曾忠,李进岚,等.提高抗结核药品固定剂量复合剂在省市级结核病定点医院推广使用的实施性研究[J].中国防痨杂志,2022,44(9):927-933.
WANG N,ZENG Z,LI J L,et al.Implementation study on promoting the use of anti-tuberculosis fixed-dose combination in provincial and prefecture tuberculosis designated hospitals[J].Chin J Antituberc,2022,44(9):927-933.(in Chinese)
[19] ALIPANAH N,JARLSBERG L,MILLER C,et al. Adherence interventions and outcomes of tuberculosis treatment:a systematic review and meta-analysis of trials and observational studies[J/OL].PLoS Med,2018,15(7)[2024-12-05].https://doi.org/10.1371/journal.pmed.1002595. |
| [1] |
MA Qiongjin, YAN Huiqin, WU Yunhua, GUO Xu, YANG Lijia, TANG Lihong, YANG Shengyuan. Influencing factors for delay in healthcare-seeking, definitive diagnosis, identification in patients with pulmonary tuberculosis in Minhang District[J]. Preventive Medicine, 2025, 37(1): 59-64. |
|
|
|
|
